Mechanism-Based Therapeutic Approaches to Cachexia

Vitamins and Hormones

Volumn 92, Issue , 2013, Pages 271-299

  Penna, Fabio ^a   Bonelli, Gabriella ^a   Baccino, Francesco M ^a   Costelli, Paola ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Adipose tissue depletion; Anorexia; Cachexia; Cytokines; Inflammation; Lipolysis; Muscle wasting; Protein turnover; Signal transduction

Indexed keywords

EID: 84876706748     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-410473-0.00011-8     Document Type: Chapter

References (156)

1. Acharyya S., Butchbach M.E., Sahenk Z., Wang H., Saji M., Carathers M., et al. Dystrophin glycoprotein complex dysfunction: A regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 2005, 8:421-432.
2. Agustsson T., Rydén M., Hoffstedt J., van Harmelen V., Dicker A., Laurencikiene J., et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Research 2007, 67:5531-5537.
3. Argilés J.M., López-Soriano J., Almendro V., Busquets S., López-Soriano F.J. Cross-talk between skeletal muscle and adipose tissue: A link with obesity?. Medicinal Research Reviews 2005, 25:49-65.
4. Attard-Montalto S.P., Camacho-Hubner C., Cotteril A.M., D'Souza-Li L., Bartlett K., Halliday D., et al. Changes in protein turnover, IGF-I and IGF binding proteins in children with cancer. Acta Pediatrica 1998, 87:54-60.
5. Aversa Z., Bonetto A., Penna F., Costelli P., Di Rienzo G., Lacitignola A., et al. Changes in myostatin signaling in non-weight-losing cancer patients. Annals of Surgical Oncology 2012, 19:1350-1356.
6. Barber M.D., Fearon K.C. Tolerance and incorporation of a high-dose eicosapentaenoic acid diester emulsion by patients with pancreatic cancer cachexia. Lipids 2001, 36:347-351.
7. Bayliss T.J., Smith J.T., Schuster M., Dragnev K.H., Rigas J.R. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opinion on Biological Therapy 2011, 11:1663-1668.
8. Beck S.A., Smith K.L., Tisdale M.J. Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Research 1991, 51:6089-6093.
9. Bianchi G., Marzocchi R., Agostini F., Marchesini G. Update on nutritional supplementation with branched-chain amino acids. Current Opinion in Clinical Nutrition and Metabolic Care 2005, 8:83-87.
10. Bing C. Lipid mobilization in cachexia: Mechanisms and mediators. Current Opinion in Supportive and Palliative Care 2011, 5:356-360.
11. British National Formulary. Vol. 58, London: British Medical Association, September 2009.
12. Bonetto A., Aydogdu T., Kunzevitzky N., Guttridge D.C., Khuri S., Koniaris L.G., et al. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One 2011, 6:e22538.
13. Bonetto A., Penna F., Minero V.G., Reffo P., Bonelli G., Baccino F.M., et al. Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice. Current Cancer Drug Targets 2009, 9:608-616.
14. Boppart M.D., Hirshman M.F., Sakamoto K., Fielding R.A., Goodyear L.J. Static stretch increases c-Jun NH2-terminal kinase activity and p38 phosphorylation in rat skeletal muscle. American Journal of Physiology. Cell Physiology 2001, 280:C352-C358.
15. Briot K., Garnero P., Le Henanff A., Dougados M., Roux C. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor alpha treatment. Annals of the Rheumatic Diseases 2005, 64:1137-1140.
16. Bruera E., Neumann C.M., Pituskin E., Calder K., Ball G., Hanson J. Thalidomide in patients with cachexia due to terminal cancer: Preliminary report. Annals of Oncology 1999, 10:857-859.
17. Bruun J.M., Lihn A.S., Verdich C., Pedersen S.B., Toubro S., Astrup A., et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. American Journal of Physiology. Endocrinology and Metabolism 2003, 285:E527-E533.
18. Bryson, N. (2008). Combination for treatment of diabetes mellitus. WO2008151415.
19. Cangiano C., Laviano A., Meguid M.M. Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients. Journal of the National Cancer Institute 1996, 88:550-552.
20. Carlson M.E., Suetta C., Conboy M.J., Aagaard P., Mackey A., Kjaer M., et al. Molecular aging and rejuvenation of human muscle stem cells. EMBO Molecular Medicine 2009, 1:381-391.
21. Chasen M., Hirschman S.Z., Bhargava R. Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia/cachexia. Journal of the American Medical Directors Association 2011, 12:62-67.
22. Chen S.E., Gerken E., Zhang Y., Zhan M., Mohan R.K., Li A.S., et al. Role of TNF-{alpha} signaling in regeneration of cardiotoxin-injured muscle. American Journal of Physiology. Cell Physiology 2005, 289:C1179-C1187.
23. Chung T.H., Yen-Ping Kuo M., Chen J.K., Huang D.M. YC-1 rescues cancer cachexia by affecting lipolysis and adipogenesis. International Journal of Cancer 2011, 9:2274-2283.
24. Clarke S., Gebbie C., Sweeney C., Olzewski N., Smith J. A phase I, pharmacokinetic (PK) and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer 2009, Abstracts p.53.
25. Coletti D., Moresi V., Adamo S., Molinaro M., Sassoon D. Tumor necrosis factor-alpha gene transfer induces cachexia and inhibits muscle regeneration. Genesis 2005, 43:120-128.
26. Coletti D., Yang E., Marazzi G., Sassoon D. TNFalpha inhibits skeletal myogenesis through a PW1-dependent pathway by recruitment of caspase pathways. The EMBO Journal 2002, 21:631-642.
27. Combaret L., Ralliere C., Taillandier D., Tanaka K., Attaix D. Manipulation of the ubiquitin-proteasome pathway in cachexia: Pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats. Molecular Biology Reports 1999, 26:95-101.
28. +-dependent proteolytic systems in the muscle of tumor-bearing rats. Cytokine 2002, 19:1-5.
29. Costelli P., Carbó N., Tessitore L., Bagby G.J., Lopez-Soriano F.J., Argilès J.M., et al. Tumour necrosis factor-α mediates changes in tissue protein turnover in a rat cancer cachexia model. The Journal of Clinical Investigation 1993, 92:2783-2789.
30. Costelli P., Llovera M., Carbó N., García-Martínez C., López-Soriano F.J., Argilés J.M. Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130). Cancer Letters 1995, 95:33-38.
31. Costelli P., Muscaritoli M., Bossola M., Penna F., Reffo P., Bonetto A., et al. IGF-1 is downregulated in experimental cancer cachexia. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 2006, 291:R674-R683.
32. Das S.K., Eder S., Schauer S., Diwoky C., Temmel H., Guertl B., et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science 2011, 333:233-238.
33. Das B.K., Mishra S., Padhi P.K., Manish R., Tripathy R., Sahoo P.K., et al. Pentoxifylline adjunct improves prognosis of human cerebral malaria in adults. Tropical Medicine & International Health 2003, 8:680-684.
34. de Heredia F.P., Gómez-Martínez S., Marcos A. Obesity, inflammation and the immune system. The Proceedings of the Nutrition Society 2012, 20:1-7.
35. Dodd S.L., Hain B., Senf S.M., Judge A.R. Hsp27 inhibits IKKbeta-induced NF-kappaB activity and skeletal muscle atrophy. The FASEB Journal 2009, 23:3415-3423.
36. Durham W.J., Dillon E.L., Sheffield-Moore M. Inflammatory burden and amino acid metabolism in cancer cachexia. Current Opinion in Clinical Nutrition and Metabolic Care 2009, 12:72-77.
37. Enomoto A., Rho M.C., Fukami A., Hiraku O., Komiyama K., Hayashi M. Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist. Biochemical and Biophysical Research Communications 2004, 323:1096-1102.
38. Evans W.J., Morley J.E., Argilès J., Bales C., Baracos V., Guttridge D., et al. Cachexia: A new definition. Clinical Nutrition 2008, 27:793-799.
39. Fallowfield L. Quality of life: A new perspective for cancer patients. Nature Reviews. Cancer 2002, 2:873-879.
40. Fearon K., Strasser F., Anker S.D., Bosaeus I., Bruera E., Fainsinger R.L., et al. Definition and classification of cancer cachexia: An international consensus. The Lancet Oncology 2011, 12:489-495.
41. Fearon K.C., von Meyenfeldt M.F., Moses A.G., Van Geenen R., Roy A., Gouma D.J., et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: A randomised double blind trial. Gut 2003, 52:1479-1486.
42. Fearon K.C., Voss A.C., Hustead D.S., Cancer Cachexia Study Group Definition of cancer cachexia: Effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. The American Journal of Clinical Nutrition 2006, 83:1345-1350.
43. Fide E., Bregman T., Kirkham T.C. Endocannabinoids and food intake: Newborn suckling and appetite regulation in adulthood. Experimental Biology and Medicine 2005, 230:225-234.
44. Ghezzi P., Cerami A. Tumor necrosis factor as a pharmacological target. Molecular Biotechnology 2005, 31:239-244.
45. Glass D.J. Signaling pathways perturbing muscle mass. Current Opinion in Clinical Nutrition and Metabolic Care 2010, 13:225-229.
46. Goldberg R.M., Loprinzi C.L., Mailliard J.A., O'Fallon J.R., Krook J.E., Ghosh C., et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology 1995, 13:2856-2859.
47. Gordon J.N., Trebble T.M., Ellis R.D., Duncan H.D., Johns T., Goggin P.M. Thalidomide in the treatment of cancer cachexia: A randomised placebo controlled trial. Gut 2005, 54:540-545.
48. Grossberg A.J., Scarlett J.M., Marks D.L. Hypothalamic mechanisms in cachexia. Physiology & Behavior 2010, 100:478-489.
49. Gulen S.T., Karadag F., Karul A.B., Kilicarslan N., Ceylan E., Kuman N.K., et al. Adipokines and systemic inflammation in weight-losing lung cancer patients. Lung 2012, 190:327-332.
50. Guttridge D.C., Mayo M.W., Madrid L.V., Wang C.Y., Baldwin A.S. NFkappaB-induced loss of MyoD messenger RNA: Possible role in muscle decay and cachexia. Science 2000, 289:2363-2366.
51. Haddad F., Adams G.R. Inhibition of MAP/ERK kinase prevents IGF-I-induced hypertrophy in rat muscles. Journal of Applied Physiology 2004, 96:203-210.
52. Haslett P.A. Anticytokine approaches to the treatment of anorexia and cachexia. Seminars in Oncology 1998, 25:53-57.
53. Huey K.A. Regulation of HSP25 expression and phosphorylation in functionally overloaded rat plantaris and soleus muscles. Journal of Applied Physiology 2006, 100:451-456.
54. Ikeda U., Shimada K. Statins and monocytes. Lancet 1999, 353:2070.
55. Ito T., Ando H., Suzuki T., Ogura T., Hotta K., Imamura Y., et al. Identification of a primary target of thalidomide teratogenicity. Science 2010, 327:1345-1350.
56. Jatoi A., Dakhil S.R., Nguyen P.L., Sloan J.A., Kugler J.W., Rowland K.M., et al. A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: Results from N00C1 from the North Central Cancer Treatment Group. Cancer 2007, 110:1396-1403.
57. Jatoi A., Rowland K., Loprinzi C.L., Sloan J.A., Dakhil S.R., MacDonald N., et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: A North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. Journal of Clinical Oncology 2004, 22:2469-2476.
58. Kadowaki M., Kanazawa T. Amino acids as regulators of proteolysis. The Journal of Nutrition 2003, 133:2052S-2056S.
59. Kato K., Ito H., Kamei K., Iwamoto I., Inaguma Y. Innervation-dependent phosphorylation and accumulation of alphaB-crystallin and Hsp27 as insoluble complexes in disused muscle. The FASEB Journal 2002, 16:1432-1434.
60. Kawano F., Matsuoka Y., Oke Y., Higo Y., Terada M., Wang X.D., et al. Role(s) of nucleoli and phosphorylation of ribosomal protein S6 and/or HSP27 in the regulation of muscle mass. American Journal of Physiology. Cell Physiology 2007, 293:C35-C44.
61. Kerem M., Ferahkose Z., Yilmaz U.T., Pasaoglu H., Ofluoglu E., Bedirli A., et al. Adipokines and ghrelin in gastric cancer cachexia. World Journal of Gastroenterology 2008, 14:3633-3641.
62. Khan Z.H., Simpson E.J., Cole A.T., Holt M., MacDonald I., Pye D., et al. Oesophageal cancer and cachexia: The effect of short-term treatment with thalidomide on weight loss and lean body mass. Alimentary Pharmacology & Therapeutics 2003, 17:677-682.
63. Kimura Y., Sumiyoshi M. Antitumor and antimetastatic actions of eicosapentaenoic acid ethylester and its by-products formed during accelerated stability testing. Cancer Science 2005, 96:441-450.
64. Kishimoto, C. (1996). Chugai Pharmaceutical Co LTD. Therapeutic agent for disease due to IL-6 production. JP8169846.
65. Klein T.W., Lane B., Newton C.A., Friedman H. The cannabinoid system and cytokine network. Proceedings of the Society for Experimental Biology and Medicine 2000, 225:1-8.
66. Körber J., Pricelius S., Heidrich M., Müller M.J. Increased lipid utilization in weight losing and weight stable cancer patients with normal body weight. European Journal of Clinical Nutrition 1999, 53:740-745.
67. Lago F., Dieguez C., Gómez-Reino J., Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine & Growth Factor Reviews 2007, 18:313-325.
68. Lai K.-M., Gonzalez M., Poueymirou W.T., Kline W.O., Na E., Zlotchenko E., et al. Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy. Molecular and Cellular Biology 2004, 24:9295-9304.
69. Laurencikiene J., Stenson B.M., Arvidsson Nordström E., Agustsson T., Langin D., Isaksson B., et al. Evidence for an important role of CIDEA in human cancer cachexia. Cancer Research 2008, 68:9247-9254.
70. Laviano A., Meguid M.M., Inui A., Muscaritoli M., Rossi Fanelli F. Therapy insight: Cancer anorexia-cachexia syndrome-When all you can eat is yourself. Nature Clinical Practice. Oncology 2005, 2:158-165.
71. Laviano A., Meguid M.M., Rossi Fanelli F. Improving food intake in anorectic cancer patients. Current Opinion in Clinical Nutrition and Metabolic Care 2003, 6:421-426.
72. Laviano A., Meguid M.M., Rossi-Fanelli F. Cancer anorexia: Clinical implications, pathogenesis, and therapeutic strategies. The Lancet Oncology 2003, 4:686-694.
73. Lee C., Raffaghello L., Brandhorst S., Safdie F.M., Bianchi G., Martin-Montalvo A., et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Science Translational Medicine 2012, 4:124ra27.
74. Li Y.P., Chen Y., John J., Moylan J., Jin B., Mann D.L., et al. TNF-α acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. The FASEB Journal 2005, 19:362-370.
75. Li J.P., Lu L., Wang L.J., Zhang F.R., Shen W.F. Increased serum levels of S100B are related to the severity of cardiac dysfunction, renal insufficiency and major cardiac events in patients with chronic heart failure. Clinical Biochemistry 2011, 44:984-988.
76. Li H.H., Willis M.S., Lockyer P., Miller N., McDonough H., Glass D.J., et al. Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins. The Journal of Clinical Investigation 2007, 117:3211-3223.
77. Liu Y., Jia Z., Dong L., Wang R., Qiu G. A randomized pilot study of atractylenolide I on gastric cancer cachexia patients. Evidence-Based Complementary and Alternative Medicine: eCAM 2008, 5:337-344.
78. Liu Q., Xu W.G., Luo Y., Han F.F., Yao X.H., Yang T.Y., et al. Cigarette smoke-induced skeletal muscle atrophy is associated with up-regulation of USP-19 via p38 and ERK MAPKs. Journal of Cellular Biochemistry 2011, 112:2307-2316.
79. Lopez A.P., Roque Figuls M., Cuchi G.U., Berenstein E.G., Pasies B.A., Alegre M.B., et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. Journal of Pain and Symptom Management 2004, 27:360-369.
80. López-Soriano J., Carbó N., Tessitore L., López-Soriano F.J., Argilés J.M. Leptin and tumor growth in rats. International Journal of Cancer 1999, 81:726-729.
81. Loprinzi C.L., Kruger J.W., Sloan J.A. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology 1999, 17:3299-3306.
82. Mantovani G., Macciò A., Madeddu C., Serpe R., Massa E., Dessì M., et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. The Oncologist 2010, 15:200-211.
83. Marcora S.M., Chester K.R., Mittal G., Lemmey A.B., Maddison P.J. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. The American Journal of Clinical Nutrition 2006, 84:1463-1472.
84. Martín A.I., Castillero E., Granado M., López-Menduiña M., Villanúa M.A., López-Calderón A. Adipose tissue loss in adjuvant arthritis is associated with a decrease in lipogenesis, but not with an increase in lipolysis. The Journal of Endocrinology 2008, 197:111-119.
85. Matthys P., Heremans H., Opdenakker G., Billiau A. Anti-interferon-gamma antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. European Journal of Cancer 1991, 27:182-187.
86. Meng W., Swenson L.L., Fitzgibbon M.J., Hayakawa K., Ter Haar E., Behrens A.E., et al. Structure of mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 suggests a bifunctional switch that couples kinase activation with nuclear export. The Journal of Biological Chemistry 2002, 277:37401-37405.
87. Mihaylova M.M., Shaw R.J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nature Cell Biology 2011, 13:1016-1023.
88. Moresi V., Pristera A., Scicchitano B.M., Molinaro M., Teodori L., Sassoon D., et al. Tumor necrosis factor-alpha inhibition of skeletal muscle regeneration is mediated by a caspase-dependent stem cell response. Stem Cells 2008, 26:997-1008.
89. Moss M.L., Jin S.L., Milla M.E., Bickett D.M., Burkhart W., Carter H.L., et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997, 385:733-736.
90. Murumkar P.R., DasGupta S., Chandani S.R., Giridhar R., Yadav M.R. Novel TACE inhibitors in drug discovery: A review of patented compounds. Expert Opinion on Therapeutic Patents 2010, 20:31-57.
91. Muscaritoli M., Anker S.D., Argilés J., Aversa Z., Bauer J.M., Biolo G., et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) " cachexia-anorexia in chronic wasting diseases" and " nutrition in geriatrics". Clinical Nutrition 2010, 29:154-159.
92. Muscaritoli M., Bossola M., Aversa Z., Bellantone R., Rossi Fanelli F. Prevention and treatment of cancer cachexia: New insights into an old problem. European Journal of Cancer 2006, 42:31-41.
93. Muscaritoli M., Costelli P., Bossola M., Grieco G., Bonelli G., Bellantone R., et al. Effects of simvastatin administration in an experimental model of cancer cachexia. Nutrition 2003, 19:936-939.
94. Nakashima J., Tachibana M., Ueno M., Miyajima A., Baba S., Murai M. Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clinical Cancer Research 1998, 4:1743-1748.
95. Nakashima K., Yakabe Y. AMPK activation stimulates myofibrillar protein degradation and expression of atrophy-related ubiquitin ligases by increasing FOXO transcription factors in C2C12 myotubes. Bioscience, Biotechnology, and Biochemistry 2007, 71:1650-1656.
96. Nara-Ashizawa N., Akiyama Y., Maruyama K., Tsukada T., Yamaguchi K. Lipolytic and lipoprotein lipase (LPL)-inhibiting activities produced by a human lung cancer cell line responsible for cachexia induction. Anticancer Research 2001, 21:3381-3387.
97. Neary N.M., Small C.J., Wren A.M., Lee J.L., Druce M.R., Palmieri C., et al. Ghrelin increases energy intake in cancer patients with impaired appetite: Acute, randomized, placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism 2004, 89:2832-2836.
98. Nicolas N., Marazzi G., Kelley K., Sassoon D. Embryonic deregulation of muscle stress signaling pathways leads to altered postnatal stem cell behavior and a failure in postnatal muscle growth. Developmental Biology 2005, 281:171-183.
99. Nienhuis H.L., Westra J., Smit A.J., Limburg P.C., Kallenberg C.G., Bijl M. AGE and their receptor RAGE in systemic autoimmune diseases: An inflammation propagating factor contributing to accelerated atherosclerosis. Autoimmunity 2009, 42:302-304.
100. Niewczas M.A., Gohda T., Skupien J., Smiles A.M., Walker W.H., Rosetti F., et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. Journal of the American Society of Nephrology 2012, 23:507-515.
101. Noori N., Kovesdy C.P., Dukkipati R., Feroze U., Molnar M.Z., Bross R., et al. Racial and ethnic differences in mortality of hemodialysis patients: Role of dietary and nutritional status and inflammation. American Journal of Nephrology 2011, 33:157-167.
102. Norrby M., Tågerud S. Mitogen-activated protein kinase-activated protein kinase 2 (MK2) in skeletal muscle atrophy and hypertrophy. Journal of Cellular Physiology 2010, 223:194-201.
103. Ohtori S., Miyagi M., Eguchi Y., Inoue G., Orita S., Ochiai N., et al. Efficacy of epidural administration of anti-interleukin-6 receptor antibody onto spinal nerve for treatment of sciatica. European Spine Journal 2012, 21:2079-2084.
104. Palacios D., Mozzetta C., Consalvi S., Caretti G., Saccone V., Proserpio V., et al. TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell 2010, 7:455-469.
105. Patra S.K., Arora S. Integrative role of neuropeptides and cytokines in cancer anorexia-cachexia syndrome. Clinica Chimica Acta 2012, 413:1025-1034.
106. Pedersen B.K., Febbraio M.A. Muscle as an endocrine organ: Focus on muscle-derived interleukin-6. Physiological Reviews 2008, 88:1379-1406.
107. Penna F., Bonetto A., Muscaritoli M., Costamagna D., Minero V.G., Bonelli G., et al. Muscle atrophy in experimental cancer cachexia: Is the IGF-1 signaling pathway involved?. International Journal of Cancer 2010, 127:1706-1717.
108. Penna F., Costamagna D., Camperi A., Muscaritoli M., Baccino F.M., Bonelli G. Protein kinases in the pathogenesis of muscle wasting. Protein Kinases/Book 2 2012, InTech, Rijeka, Croatia, in press. G. Da Silva Xavier (Ed.).
109. Penna F., Costamagna D., Pin F., Camperi A., Fanzani A., Chiarpotto E.M., et al. Autophagic Degradation Contributes to Muscle Wasting in Cancer Cachexia. American Journal of Pathology 2013, doi:pii: S0002-9440(13)00033-3. 10.1016/j.ajpath.2012.12.023. [Epub ahead of print].
110. Penna F., Costamagna D., Fanzani A., Bonelli G., Baccino F.M., Costelli P. Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. PLoS One 2010, 5:e13604.
111. Pisters P.W., Pearlstone D.B. Protein and amino acid metabolism in cancer cachexia: Investigative techniques and therapeutic interventions. Critical Reviews in Clinical Laboratory Sciences 1993, 30:223-272.
112. Popa C., Netea M.G., Radstake T.R., van Riel P.L., Barrera P., van der Meer J.W. Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Annals of the Rheumatic Diseases 2005, 64:1195-1198.
113. Prado C.M., Antoun S., Sawyer M.B., Baracos V.E. Two faces of drug therapy in cancer: Drug-related lean tissue loss and its adverse consequences to survival and toxicity. Current Opinion in Clinical Nutrition and Metabolic Care 2011, 14:250-254.
114. Prado C.M., Lieffers J.R., McCargar L.J., Reiman T., Sawyer M.B., Martin L., et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. The Lancet Oncology 2008, 9:629-635.
115. Prehn R.T. The immune reaction as a stimulator of tumor growth. Science 1972, 176:170-171.
116. Raffaghello L., Lee C., Safdie F.M., Wei M., Madia F., Bianchi G., et al. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:8215-8220.
117. Raffaghello L., Safdie F., Bianchi G., Dorff T., Fontana L., Longo V.D. Fasting and differential chemotherapy protection in patients. Cell Cycle 2010, 9:4474-4476.
118. Reid J., Mills M., Cantwell M., Cardwell C.R., Murray L.J., Donnelly M. Thalidomide for managing cancer cachexia. Cochrane Database of Systematic Reviews 2012, 4:CD008664.
119. Rivadaneira D.E., Evoy D., Fahey T.J., Lieberman R.D., Daly J.M. Nutritional support of the cancer patient. CA: A Cancer Journal for Clinicians 1998, 48:69-80.
120. Romanello V., Guadagnin E., Gomes L., Roder I., Sandri C., Petersen Y., et al. Mitochondrial fission and remodelling contributes to muscle atrophy. The EMBO Journal 2010, 29:1774-1785.
121. Rommel C., Bodine S.C., Clarke B.A., Rossman R., Nunez L., Stitt T.N., et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nature Cell Biology 2001, 3:1009-1013.
122. Rommel C., Clarke B.A., Zimmermann S., Nunez L., Rossman R., Reid K., et al. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 1999, 286:1738-1741.
123. Rosner M., Hanneder M., Siegel N., Valli A., Hengstschläger M. The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners. Mutation Research 2008, 658:234-246.
124. Ross P.J., Ashley S., Norton A., Priest K., Waters J.S., Eisen T., et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?. British Journal of Cancer 2004, 90:1905-1911.
125. Ruff R.L., Secrist D. Inhibitors of prostaglandin synthesis or cathepsin B prevent muscle wasting due to sepsis in the rat. The Journal of Clinical Investigation 1984, 73:1483-1486.
126. Sakamoto K., Aschenbach W.G., Hirshman M.F., Goodyear L.J. Akt signaling in skeletal muscle: Regulation by exercise and passive stretch. American Journal of Physiology. Endocrinology and Metabolism 2003, 285:E1081-E1088.
127. Sakurai Y., Klein S. Metabolic alterations in patients with cancer: Nutritional implications. Surgery Today 1998, 28:247-257.
128. Sandri M., Sandri C., Gilbert A., Skurk C., Calabria E., Picard A., et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004, 117:399-412.
129. Seruga B., Zhang H., Bernstein L.J., Tannock I.F. Cytokines and their relationship to the symptoms and outcome of cancer. Nature Reviews. Cancer 2008, 8:887-899.
130. Shan X., Yeo G.S. Central leptin and ghrelin signalling: Comparing and contrasting their mechanisms of action in the brain. Reviews in Endocrine & Metabolic Disorders 2011, 12:197-209.
131. Shi H., Scheffler J.M., Pleitner J.M., Zeng C., Park S., Hannon K.M., et al. Modulation of skeletal muscle fiber type by mitogen-activated protein kinase signaling. The FASEB Journal 2008, 22:2990-3000.
132. Shi H., Scheffler J.M., Zeng C., Pleitner J.M., Hannon K.M., Grant A.L., et al. Mitogen-activated protein kinase signaling is necessary for the maintenance of skeletal muscle mass. American Journal of Physiology. Cell Physiology 2009, 296:C1040-C1048.
133. Shi H., Zeng C., Ricome A., Hannon K.M., Grant A.L., Gerrard D.E. Extracellular signal-regulated kinase pathway is differentially involved in beta-agonist-induced hypertrophy in slow and fast muscles. American Journal of Physiology. Cell Physiology 2007, 292:C1681-C1689.
134. Späte U., Schulze P.C. Proinflammatory cytokines and skeletal muscle. Current Opinion in Clinical Nutrition and Metabolic Care 2004, 7:265-269.
135. Stenholm S., Harris T.B., Rantanen T., Visser M., Kritchevsky S.B., Ferrucci L. Sarcopenic obesity: Definition, cause and consequences. Current Opinion in Clinical Nutrition and Metabolic Care 2008, 11:693-700.
136. Stephens N.A., Skipworth R.J., Fearon K.C. Cachexia, survival and the acute phase response. Current Opinion in Supportive and Palliative Care 2008, 2:267-274.
137. Stitt T.N., Drujan D., Clarke B.A., Panaro F., Timofeyva Y., Kline W.O., et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Molecular Cell 2004, 14:395-403.
138. Strassmann G., Fong M., Freter C.E., Windsor S., D'Alessandro F., Nordan R.P. Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. The Journal of Clinical Investigation 1993, 92:2152-2159.
139. Tan B.H., Fearon K.C. Cachexia: Prevalence and impact in medicine. Current Opinion in Clinical Nutrition and Metabolic Care 2008, 11:400-407.
140. Tessitore L., Costelli P., Baccino F.M. Pharmacological interference with tissue protein hypercatabolism in tumor-bearing rats. The Biochemical Journal 1994, 299:71-78.
141. Thornberry N.A., Bull H.G., Calaycay J.R., Chapman K.T., Howard A.D., Kostura M.J., et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 1992, 356:768-7674.
142. Tisdale M.J. Catabolic mediators of cancer cachexia. Current Opinion in Supportive and Palliative Care 2008, 2:256-261.
143. Trayhurn P., Wood I.S. Adipokines: Inflammation and the pleiotropic role of white adipose tissue. The British Journal of Nutrition 2004, 92:347-355.
144. van de Woestijne A.P., Monajemi H., Kalkhoven E., Visseren F.L. Adipose tissue dysfunction and hypertriglyceridemia: Mechanisms and management. Obesity Reviews 2011, 12:829-840.
145. van der Meij B.S., van Bokhorst-de van der Schueren M.A., Langius J.A., Brouwer I.A., van Leeuwen P.A. n-3 PUFAs in cancer, surgery, and critical care: A systematic review on clinical effects, incorporation, and washout of oral or enteral compared with parenteral supplementation. The American Journal of Clinical Nutrition 2011, 94:1248-1265.
146. Wallace A.M., Sattar N., McMillan D.C. Effect of weight loss and the inflammatory response on leptin concentrations in gastrointestinal cancer patients. Clinical Cancer Research 1998, 4:2977-2979.
147. Walsh D., Rybicki L., Nelson K.A., Donnelly S. Symptoms and prognosis in advanced cancer. Supportive Care in Cancer 2002, 10:385-388.
148. Weed H.G., Ferguson M.L., Gaff R.L., Hustead D.S., Nelson J.L., Voss A.C. Lean body mass gain in patients with head and neck squamous cell cancer treated perioperatively with a protein- and energy-dense nutritional supplement containing eicosapentaenoic acid. Head & Neck 2011, 33:1027-1033.
149. White J.P., Baynes J.W., Welle S.L., Kostek M.C., Matesic L.E., Sato S., et al. The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse. PLoS One 2011, 6:e24650.
150. Wilkes E.A., Freeman J.G. Thalidomide: An effective anabolic agent in gastrointestinal cancer cachexia. Alimentary Pharmacology and Therapeutics 2006, 23:445-446.
151. Winfield R.D., Delano M.J., Pande K., Scumpia P.O., Laface D., Moldawer L.L. Myeloid-derived suppressor cells in cancer cachexia syndrome: A new explanation for an old problem. Journal of Parenteral and Enteral Nutrition 2008, 32:651-655.
152. Wolfe R.R. The underappreciated role of muscle in health and disease. The American Journal of Clinical Nutrition 2006, 84:475-482.
153. Wu R., Kausar H., Johnson P., Montoya-Durango D.E., Merchant M., Rane M.J. Hsp27 regulates Akt activation and polymorphonuclear leukocyte apoptosis by scaffolding MK2 to Akt signal complex. The Journal of Biological Chemistry 2007, 282:21598-21608.
154. Yang S.Y., Hoy M., Fuller B., Sales K.M., Seifalian A.M., Winslet M.C. Pretreatment with insulin-like growth factor I protects skeletal muscle cells against oxidative damage via PI3K/Akt and ERK1/2 MAPK pathways. Laboratory Investigation 2010, 90:391-401.
155. Zabel P., Entzian P., Dalhoff K., Schlaak M. Pentoxifylline in treatment of sarcoidosis. American Journal of Respiratory and Critical Care Medicine 1997, 155:1665-1669.
156. Zhao J., Brault J.J., Schild A., Cao P., Sandri M., Schiaffino S., et al. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metabolism 2007, 6:472-483.